Hamilton Lane just posted one of the biggest earnings beats in the stock’s history, and it’s doing it from the exact zone where you’d want a long-term reversal to start.
HLNE closed today at $103.29, down 1.48% on the session after tagging a high of $105.25 — a normal pause after a sharp multi-week rally off the lows. The long-term setup: build a position in the $98–$105 zone while price holds above the reclaimed $100 level, with a weekly close below $88.52 invalidating the thesis. Target one sits at $110.52, target two (the primary objective) at $132.52 — almost exactly where Wall Street’s average price target already sits — and a stretch target at $159.73 for the position you’re willing to hold through multiple earnings cycles. This is not a two-week trade. It’s a multi-quarter thesis built on a monthly chart, and it only works if you treat it that way.
The long-term technical setup: buying the golden pocket, not the bottom tick
Zoom out to the monthly chart and HLNE’s story is simple: the stock ran from roughly $17 in 2018 to an all-time high near $204 in early 2025, then gave back more than 60% of that entire move into 2026. That’s a brutal correction on paper, but structurally it’s exactly what a healthy long-term retracement looks like — price found its floor between the 61.8% retracement ($88.52) and the 78.6% retracement ($57.21), the “golden pocket” that marks the last realistic support before a trend is fully broken. HLNE never traded meaningfully below that zone, bottomed in the low $70s to high $50s depending on the session, and has spent the better part of 2026 building a base directly on top of it.
The daily chart shows the tactical version of that same story: five months of chop between roughly $80 and $103, with the 50-day and 200-day moving averages flattening out and converging — the classic signature of a base forming, not a downtrend continuing. Price has now closed back above both averages and reclaimed $100, a level that acted as both support and resistance multiple times over the past year (the dotted polarity line on the chart). Reclaiming a multi-tested polarity level on the daily chart while sitting inside a monthly golden pocket is two independent structures agreeing on the same conclusion — that’s a stronger technical picture than either one alone.
The three retracement levels above the current price aren’t arbitrary. $110.52 is the 50% retracement of the entire 2018–2025 advance. $132.52 is the 38.2% retracement. $159.73 is the 23.6% retracement. Each one lines up with a real prior consolidation shelf on the monthly chart, which is why they’re used as the scale-out levels below instead of a random percentage move.
The fundamental case: the business is growing faster than the stock is recovering
On August 4, 2026, Hamilton Lane reported fiscal Q1 2027 results that blew past every estimate on the sheet: non-GAAP EPS of $1.94 versus a $1.53 consensus (a 32.9% beat) and revenue of $275.33 million versus $221.95 million expected (a 26.1% beat), up 56.5% year over year (MarketBeat, Investing.com). Management and advisory fees — the recurring, non-lumpy part of the business — grew 21% year over year to $161.4 million, while fee-related earnings jumped 49% to $124.5 million as margins expanded from 51% to 53% (Yahoo Finance).
The bigger structural story: Hamilton Lane’s total asset footprint (assets under management plus assets under advisement) crossed $1 trillion for the first time, with AUM at $146 billion and AUA at $905 billion, a milestone built on a 17% historical CAGR in total assets since 2005 (Investing.com, Investing.com). The firm’s newer Evergreen platform — semi-liquid private markets funds aimed at wealth-channel investors — pulled in roughly $640 million of net inflows in the quarter and now sits above $19 billion in AUM, one of the fastest-growing pieces of the business (Seeking Alpha). Management also raised the quarterly dividend to $0.60 per share, keeping the company on pace for an 11% annual dividend increase to $2.40 for fiscal 2027 — the kind of shareholder-return commitment you want to see from a company you’re planning to hold for months, not days (StockTitan).
Wall Street has responded accordingly. Keefe, Bruyette & Woods raised its target from $105 to $116 on the print, UBS moved to $131, and Oppenheimer sits at $182 — the average of nine analyst targets is $131.71, which happens to sit almost exactly on top of the 38.2% Fibonacci level this post uses as its primary target (MarketBeat). That kind of alignment between an independently-derived technical level and the Street’s fundamental valuation work is exactly the confluence a long-term swing idea should be built on.
Doing the math: position sizing for a multi-quarter hold
From an entry around $103 with a stop at $88.52, you’re risking roughly $14.50 per share. Target one at $110.52 is only about a 0.5:1 reward-to-risk — treat that level as a place to trim a small piece and move your stop to breakeven, not a profit target. Target two at $132.52 is where the real reward-to-risk shows up: roughly $29.50 of reward against $14.50 of risk, close to 2:1. The stretch target at $159.73 is closer to 3.9:1, but that leg could take multiple quarters and should be held with a much smaller remaining position and a trailing stop rather than a fixed exit.
Because the total risk per share is large relative to the entry price (about 14%), position size needs to be smaller than you’d run on a short-term breakout idea with a tight stop. This is a name you size to survive being wrong, not a name you size to maximize a quick win.
Why this is a long-term swing, not a short-term trade
A short-term swing idea lives or dies on a single trigger candle and a stop a few percent away — you’re in and out in days to a couple of weeks. This setup is different on every axis that matters: the structure is drawn from a seven-year monthly chart, not a few weeks of daily bars. The stop is 14% away, not 3-5%. The thesis depends on Hamilton Lane executing across multiple upcoming quarterly reports, not one catalyst. And the targets are built to be scaled into over months as the stock proves the reversal is real, not exited in a single trade. If you’re not willing to hold HLNE through its next two or three earnings reports and the inevitable pullbacks in between, this isn’t your setup — and that’s fine. Knowing which kind of trade you’re in before you enter is half of risk management.
Thesis invalidation: what would prove this wrong
Technical invalidation: a weekly close below $88.52, the 61.8% retracement that has held as support since the base began forming. A decisive break there reopens the door to a retest of the $71.88 fifty-two-week low and would mean the “golden pocket” reversal thesis failed — the long-term downtrend would still be intact.
Fundamental invalidation: a meaningful slowdown in fee-earning AUM growth, a reversal of the Evergreen platform’s net inflows, or a guidance cut on the fee-related earnings margin would undercut the growth story this thesis depends on. The next real test is Hamilton Lane’s fiscal Q2 2027 earnings report, expected around November 10, 2026 — flag that date as a binary risk window and reassess position size heading into it regardless of how the chart looks the week before (Investing.com).
What this means for how you’d actually trade it
Scale in rather than deploying full size at once — a starter position now, with room to add if price holds $100 through the next few weeks of consolidation. As HLNE works toward $110.52 and beyond, trail your stop up under each new higher low instead of leaving it fixed at $88.52 forever; the goal is to let the position defend itself once it’s proven the base is real. None of this works if your position size is so large that a normal 8-10% pullback inside an intact uptrend forces you out early — if you haven’t sized this the way the Risk Management Mastery series lays out, do that math before you place the first share.
Takeaway: The whole trade is the golden pocket holding. As long as HLNE stays above $88.52 on a weekly closing basis, the long-term reversal thesis remains intact, with $132.52 as the primary multi-quarter objective and $159.73 as the stretch case if the fundamental growth story keeps compounding. Professionals aren’t trying to buy the exact bottom tick here — they’re trying to buy a confirmed structural reversal with the business accelerating underneath it, and they’re sizing it small enough to actually hold through the noise between now and the next earnings report.
References
- Hamilton Lane Given New $116.00 Price Target at Keefe, Bruyette & Woods – MarketBeat
- Hamilton Lane (HLNE) Earnings Date & Report – Investing.com
- Hamilton Lane Q1 Earnings Call Highlights – Yahoo Finance
- Hamilton Lane Q1 FY27 slides: earnings surge 50%, assets top $1T – Investing.com
- Hamilton Lane Incorporated (HLNE) Q1 2027 Earnings Call Transcript – Seeking Alpha
- Hamilton Lane (NASDAQ: HLNE) lifts dividend and reports fiscal 2026 results – StockTitan
- Hamilton Lane (HLNE) Stock Forecast and Price Target 2026 – MarketBeat
- Hamilton Lane details $142B AUM private markets business – StockTitan
- Hamilton Lane Q3 2026 slides: Fee Related Earnings surge 37% as AUM hits $146B – Investing.com
